Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVA-201
- Development stage
- Preclinical
- Lead developer
- Biovista
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BVA-201 is a repositioned small molecule drug candidate developed by Biovista for the treatment of Multiple Sclerosis (MS). Identified as a tetracyclic pyrazinoindole compound, BVA-201 was discovered through Biovista's drug repositioning platform and is an existing approved drug being repurposed for its neuroprotective properties. Unlike conventional MS therapies that primarily target inflammatory pathways, BVA-201 modulates oxidative stress pathways to protect neural axons and myelin from degeneration. In preclinical studies using the MOG-induced Experimental Allergic Encephalomyelitis (EAE) mouse model, the drug demonstrated efficacy in reducing disease severity comparable to dexamethasone without associated toxicity. BVA-201 is blood-brain barrier permeable and possesses an established safety profile from its prior clinical use in other chronic indications. It is currently positioned as ready for human Proof of Concept (PoC) studies.
- Other names
- tetracyclic pyrazinoindole compound
Beyond the preview
Go deeper on BVA-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVA-201.